Retatrutide

WhatEvidence.Health · Claim Review
Retatrutide peptide causes major weight loss and improves metabolic health.
B Promising Evidence

Strong trial signal — not a consumer peptide. Retatrutide has caused large weight loss in clinical trials, but it is still investigational and should not be bought or injected outside a regulated clinical trial.

Evidence LevelModerate for trial weight loss
Best SignalObesity / overweight
Main ProblemNot approved; long-term data pending
Last ReviewedMay 23, 2026
Bottom Line

Retatrutide is a once-weekly injectable triple agonist, meaning it activates three hormone receptors involved in appetite, blood sugar, and energy balance: GIP, GLP-1, and glucagon.8 In clinical trials, pharmaceutical-grade retatrutide has produced unusually large weight loss. But products sold online as “retatrutide peptide” are unapproved and may be fake, contaminated, wrongly dosed, or the wrong ingredient entirely.8910

At a Glance

28.3%
Highest mean weight loss in Lilly’s phase 3 TRIUMPH-1 topline result6
Not approved
Not FDA-approved or approved by any regulator as of May 20268
Do not DIY
Online “research peptide” products are a safety risk910

The Claim

Claim being checked: “Retatrutide peptide is a powerful weight-loss injection that people can use to lose fat and improve metabolic health.”

This claim needs a split answer. The evidence for clinical-trial retatrutide is genuinely promising. The evidence for buying or using online retatrutide peptide is not supportive and carries clear safety concerns.

What the Evidence Shows

⚖️
Weight loss in obesity — strong early clinical signal A phase 2 randomized controlled trial found large, dose-related weight loss at 48 weeks.1 Lilly’s phase 3 TRIUMPH-1 topline result later reported up to 28.3% mean weight loss at 80 weeks with 12 mg retatrutide, compared with 2.2% on placebo.6
🩸
Type 2 diabetes — promising for A1C and weight In a phase 2 diabetes trial, retatrutide lowered HbA1c, a blood test that reflects average blood sugar, and reduced weight more than placebo.2 Lilly’s phase 3 TRANSCEND-T2D-1 topline result reported A1C reductions up to 2.0% and weight loss up to 16.8% at 40 weeks.7
🫀
Fatty liver / MASLD — large imaging signal, not yet hard outcomes In a phase 2a randomized substudy of people with metabolic dysfunction-associated steatotic liver disease (MASLD), retatrutide greatly reduced liver fat on MRI. Normal liver fat was reached by 79% of the 8 mg group and 86% of the 12 mg group at 24 weeks, compared with 0% on placebo.3
⛔
Online “retatrutide peptide” — not supported Lilly states retatrutide is legally available only through its clinical trials and says products sold outside those trials may contain unknown ingredients, harmful contaminants, too much or too little active ingredient, or the wrong ingredient.8 The FDA has also warned about unapproved retatrutide products sold as “for research purposes” or “not for human consumption.”9

What the Best Evidence Says

The best evidence comes from randomized controlled trials, where participants were assigned to retatrutide or a comparison group by chance. This design helps separate the drug’s effect from expectation, background diet changes, and natural variation.

Adults with obesity or overweight

The key peer-reviewed obesity study was a phase 2 trial in 338 adults with obesity or overweight but without type 2 diabetes. At 48 weeks, higher-dose retatrutide produced large weight reductions, with the 12 mg group reaching a mean 24.2% reduction in body weight.1

The newer phase 3 TRIUMPH-1 result is larger and longer, but it is still a company topline release rather than a full peer-reviewed paper. Lilly reported that 2,339 adults were randomized to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. Mean body weight fell by 19.0%, 25.9%, and 28.3% in the retatrutide groups, compared with 2.2% on placebo.6 The registered TRIUMPH-1 trial is listed as NCT05929066.12

Adults with type 2 diabetes

In the phase 2 diabetes trial, 281 adults with type 2 diabetes received retatrutide, placebo, or dulaglutide. Higher-dose retatrutide improved blood sugar and reduced weight, with gastrointestinal side effects such as nausea, diarrhoea, vomiting, and constipation reported more often than with placebo.2

Lilly’s phase 3 TRANSCEND-T2D-1 topline result reported A1C reductions of 1.7% to 2.0% across retatrutide doses at 40 weeks, compared with 0.8% for placebo. The 12 mg dose produced 16.8% mean weight loss, compared with 2.5% for placebo using the efficacy estimand.7

MASLD, sometimes called fatty liver disease

MASLD means metabolic dysfunction-associated steatotic liver disease. It is a condition where excess fat builds up in the liver in the setting of metabolic risk factors such as obesity, insulin resistance, or type 2 diabetes.

The retatrutide MASLD substudy was encouraging, but it mainly measured liver fat on imaging. That is useful, but it does not yet prove fewer cases of cirrhosis, liver cancer, liver failure, heart attack, stroke, or death.3

Important distinction A clinical trial drug made, stored, tested, and monitored under regulated conditions is not the same as a vial sold online as a “research peptide.” The evidence above applies to pharmaceutical-grade retatrutide used in trials, not to unverified consumer products.

Key Studies and Sources

Source N Key results
Jastreboff et al., 20231
Phase 2 human RCT		 338 Adults with obesity or overweight, without diabetes, lost up to 24.2% mean body weight at 48 weeks. Main limitation: phase 2, industry-funded, not designed for long-term outcomes.
Rosenstock et al., 20232
Phase 2 human RCT		 281 Adults with type 2 diabetes had larger HbA1c and weight reductions than placebo. Gastrointestinal side effects were the main tolerability issue.
Sanyal et al., 20243
Phase 2a RCT substudy		 98 In adults with MASLD and obesity/overweight, liver fat fell 42.9% to 82.4% at 24 weeks across retatrutide doses, while placebo increased 0.3%. This was an imaging result, not a hard liver-outcome result.
Abouelmagd et al., 20255
Systematic review/meta-analysis		 878 Across early randomized trials, body weight reduction favoured retatrutide by 14.33 percentage points. Authors still called for larger and longer trials.
TRIUMPH-1, Lilly, 20266
Topline phase 3 RCT		 2,339 Adults with obesity or overweight, without diabetes, lost up to 28.3% mean body weight at 80 weeks with 12 mg. Full peer-reviewed results are still pending.
TRANSCEND-T2D-1, Lilly, 20267
Topline phase 3 RCT		 537 Adults with type 2 diabetes had A1C reductions up to 2.0% and weight loss up to 16.8% at 40 weeks. Full peer-reviewed details are still pending.

Why We Rate It This Way

Evidence Rating
B
Grade B — Promising Evidence The weight-loss effect is large and consistent in human trials, but retatrutide is not approved, several important phase 3 results are still topline only, and long-term real-world safety is not yet established.
  • Human randomized trials show a consistent, dose-related weight-loss effect.156
  • The effect size is clinically meaningful in trial settings, especially in adults with obesity or overweight.16
  • Confidence is lowered because Lilly developed and funded the key trials, and some phase 3 findings are company topline results rather than full peer-reviewed papers.67
  • Safety needs more time. Gastrointestinal side effects are common, and long-term outcomes such as heart attacks, strokes, kidney outcomes, liver events, and mortality are still being studied.28
  • The rating applies to regulated clinical-trial retatrutide. It does not apply to unapproved online peptide products.89

A Grade B does not mean “safe to buy.” It means the medical evidence is promising enough to justify continued clinical development and careful regulatory review. It does not justify self-injection with unverified products.

Safety Note

Do not use online retatrutide peptide Retatrutide is not approved for public use. Lilly says it is legally available only through clinical trials. The FDA warns that unapproved products sold as “research” retatrutide may be of unknown quality and harmful. The TGA warns that unregistered GLP-1 products sold online may be fake, contain harmful ingredients, or fail to meet normal quality, safety, and efficacy standards; it has also reported counterfeit weight-loss products claiming to contain GLP-1 analogues.891011

In Lilly’s TRIUMPH-1 topline release, common adverse events included nausea, diarrhoea, constipation, and vomiting. These were more common with retatrutide than placebo and generally increased at higher doses.6

Other safety questions still matter: dehydration from vomiting or diarrhoea, gallbladder disease, pancreatitis, kidney stress during illness, excessive weight loss, lean-mass loss, interactions with diabetes medicines, pregnancy exposure, mental health effects, and long-term cardiovascular outcomes. A body-composition analysis in people with type 2 diabetes reported that retatrutide reduced fat mass, but lean-mass monitoring still matters when weight loss is large.4 Trial monitoring does not make unsupervised use safe.

If you have already used an online peptide product and feel unwell, contact a healthcare professional. In Australia, suspected side effects or product-quality concerns can be reported to the TGA.10

Quick Questions

Is retatrutide FDA-approved?

No. Lilly states that retatrutide is not approved by the FDA or any regulatory agency and is still being studied in clinical trials.8

Is retatrutide the same as Ozempic or Mounjaro?

No. Ozempic is semaglutide, a GLP-1 receptor agonist. Mounjaro is tirzepatide, a GIP/GLP-1 receptor agonist. Retatrutide is a triple agonist that targets GIP, GLP-1, and glucagon receptors.8

Can retatrutide help fatty liver?

It may reduce liver fat in some people with MASLD, based on a small phase 2a substudy. But we do not yet know whether it reduces serious liver outcomes such as cirrhosis or liver failure.3

Can I buy retatrutide peptide for “research use”?

That is exactly the risky grey-market route regulators warn about. The FDA has warned companies selling unapproved retatrutide products under “research use” language directly to consumers.9

What This Means for You

If you are reading about retatrutide because of obesity or weight-related disease, the science is worth watching. The clinical-trial results are among the strongest weight-loss signals seen so far for an injectable obesity medicine.

But retatrutide is not an approved treatment. It is not something to order online, mix, dose, or inject yourself.

The practical answer is: promising medicine in trials, unsafe bet as an online peptide.

References & Sources
  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389:514–526. PMID 37366315 NEJM Phase 2 Human RCT
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023. DOI 10.1016/S0140-6736(23)01053-X PMID 37385280 Phase 2 Human RCT
  3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. Nature Medicine PMID 38858523 Phase 2a RCT Substudy
  4. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes. The Lancet Diabetes & Endocrinology. 2025. PMID 40609566 Human Trial Analysis
  5. Abouelmagd AA, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. 2025. PMC full text Systematic Review / Meta-analysis
  6. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Published May 21, 2026. Company topline release Phase 3 Topline Results
  7. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Published March 19, 2026. Company topline release Phase 3 Topline Results
  8. Eli Lilly and Company. What to know about retatrutide. Medically reviewed; last updated May 2026. Lilly explainer Manufacturer / Regulatory Status
  9. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of February 4, 2026. FDA safety information Regulatory Safety Source
  10. Therapeutic Goods Administration. Imported unregistered GLP-1 weight-loss products. Published September 29, 2025. TGA safety advisory Regulatory Safety Source
  11. Therapeutic Goods Administration. Counterfeit weight loss products claiming to contain GLP-1. Published March 2, 2026. TGA safety advisory Regulatory Safety Source
  12. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066. ClinicalTrials.gov Trial Registry
Last reviewed: May 23, 2026 · Reviewed by a practising Australian GP · WhatEvidence.Health
Medical disclaimer: This article is general health information and is not personal medical advice. It does not diagnose, prescribe, or recommend retatrutide. Retatrutide is investigational and should not be used outside a regulated clinical trial unless and until it is approved and prescribed by an appropriately qualified clinician.

Similar Posts